Proficio Capital Partners LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Proficio Capital Partners LLC purchased a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 38,669 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,762,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. CWA Asset Management Group LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Jazz Pharmaceuticals by 135.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $9,335,000. Moloney Securities Asset Management LLC bought a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $464,000. Finally, Pacer Advisors Inc. boosted its position in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JAZZ has been the topic of several analyst reports. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Cantor Fitzgerald downgraded Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $182.47.

Jazz Pharmaceuticals Stock Down 2.3 %

JAZZ opened at $140.22 on Tuesday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company has a market capitalization of $8.52 billion, a PE ratio of 19.75, a P/E/G ratio of 1.04 and a beta of 0.56. The stock’s fifty day moving average is $127.01 and its 200-day moving average is $119.37. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $148.06.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 3,800 shares of the firm’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the sale, the chief executive officer now owns 464,058 shares in the company, valued at $66,940,366.50. The trade was a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,113 shares of company stock valued at $2,551,834 over the last three months. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.